Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05359445 | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | PHASE1 | ACTIVE NOT_RECRUITING | 95 | — | — | May 19, 2022 | Dec 1, 2029 | Apr 30, 2026 | 21 | Germany |
| Arm | Type | Description |
|---|---|---|
| Dose-Finding IMA401 TCER® Monotherapy (Phase Ia) | EXPERIMENTAL | Dose-Finding Escalation/De-escalation with IMA401 TCER® (Phase Ia) |
| Dose-Finding Combination Therapy with IMA401 TCER® and Pembrolizumab (Phase Ia) | EXPERIMENTAL | Dose-Finding Escalation/De-escalation of combination therapy with IMA401 TCER and pembrolizumab (Phase Ia) |
| Extension IMA401 TCER® Monotherapy (Phase Ib) | EXPERIMENTAL | IMA401 monotherapy extension cohort following the determination of the recommended dose for extension (RDE) (Phase Ib) |
| Name | Type | Description |
|---|---|---|
| IMA401 (Phase Ia) | BIOLOGICAL | Intravenous infusions in escalating dose levels |
| Pembrolizumab (Phase Ia) | BIOLOGICAL | Intravenous infusions in escalating dose levels for combination of IMA 401 and Pembrolizumab |
| IMA 401 (Phase Ib) | BIOLOGICAL | Treatment at recommended dose for extension (RDE) |
Inclusion Criteria: * Patients must have voluntarily signed a written ICF, be able to understand and comply with clinical trial procedures * Patients ≥ 18 years old * Patients must have pathologically confirmed and documented advanced and/or metastatic NSCLC or HNSCC, other solid tumor may be consi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |